Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Lilly's ramucirumab scores a marginal gain for lung cancer patients

Eli Lilly wrestled its way into the spotlight at ASCO Saturday morning with evidence that its cancer drug ramucirumab delivers a marginal benefit for patients suffering from advanced non-small cell lung cancer. And analysts quickly heralded the data, saying it should help pave the way to quickly broaden the market for this drug.

AbbVie's leukemia drug program continues to wow analysts in early study

AbbVie's experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 combined with rituximab registered an 84% overall response rate among patients with chronic lymphocytic leukemia.

UPDATED: Clovis preps for a blockbuster showdown with AstraZeneca

Clovis Oncology has come out of the gate at ASCO with updated--and promising--data on its targeted lung cancer drug CO-1686, offering fresh evidence of its durability and effectiveness.

Roche partners with Roche on 'breakthrough' PD-L1 cancer program

Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA's coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.

PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo

Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.

Isis surges on promising head-to-head thrombosis drug study

Shares of Isis Pharmaceuticals surged 9% this morning as the Carlsbad, CA-based antisense drug developer posted positive outcomes for a head-to-head Phase II study comparing ISIS-FXIRx with Lovenox on thrombosis. The biotech says the top 300 mg dose of its therapy beat out the widely used anticoagulant, lowering the number of blood clots while reducing the number of bleeding incidents.

Novartis, Boehringer vie for COPD market share with combo meds

Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.

R.I.P.: Merck and Endocyte yank vintafolide app

Now that the ovarian cancer drug vintafolide has crumbled in Phase III, Merck and its partner Endocyte have pulled their conditional marketing application in Europe and are moving to close down the study.

Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data

The latest download of data on a pair of rival therapies for lethal cases of idiopathic pulmonary fibrosis wowed researchers in the field, producing clear evidence of their ability to slow down the lung disease and offering patients a possible set of game-changing treatments.

Bluebird bio buoyed by news of looming trial data

Shares of Cambridge, MA-based bluebird bio shot up after CEO Nick Leschly noted the looming arrival of early-stage data for its drug LentiGlobin, designed to treat the rare blood disorder beta thalassemia.